In an apparent nod to growing concern over the rapidly climbing costs of cancer drugs, Genentech announced that it would cap the total cost of its drug Avastin at $55,000 a year for patients below a certain income level. The announcement came as the drug, approved two years ago as a treatment for colorectal cancer, received a new approval for use in treating advanced nonsmall-cell lung cancer. Avastin costs about $4,400 per month for treatment of colorectal cancer. Twice as much of the drug is needed for lung cancer, bringing the cost to $8,800 a month, or more than $100,000 a year. Read the full story.
Genentech caps cost of cancer drug
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.